(Q43622987)

25 November 2017

title

Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis (English)

1 reference

25 November 2017

0 references

1 reference

J J Caro

1

1 reference

25 November 2017

D Getsios

2

1 reference

25 November 2017

G Raggio

3

1 reference

25 November 2017

G Caro

4

1 reference

25 November 2017

L Black

5

1 reference

25 November 2017

publication date

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

41

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

456-464

1 reference

Prevalence of migraine headache in Canada: a population-based survey.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Burden of migraine in the United States: disability and economic costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Quality-of-life assessment in patients with headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Increasing incidence of medically recognized migraine headache in a United States population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Naratriptan: an alternative for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

The measurement of indirect costs in the health economics evaluation literature. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

The Migraine ACE Model: Evaluating the Impact on Time Lost and Medical Resource Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01083.X

10.1046/J.1526-4610.2001.01083.X

21 January 2018

Identifiers

DOI

1 reference

release_nlidw3djqrb2nlhrzzdtvjc3j4

25 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nlidw3djqrb2nlhrzzdtvjc3j4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference